



# DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

## Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters.

<b>Citation</b>	Mears, Jessica, Ibrahim Abubakar, Theodore Cohen, Timothy D McHugh, and Pam Sonnenberg. 2015. "Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review." <i>BMJ Open</i> 5 (1): e005636. doi:10.1136/bmjopen-2014-005636. <a href="http://dx.doi.org/10.1136/bmjopen-2014-005636">http://dx.doi.org/10.1136/bmjopen-2014-005636</a> .
<b>Published Version</b>	<a href="https://doi.org/10.1136/bmjopen-2014-005636">doi:10.1136/bmjopen-2014-005636</a>
<b>Accessed</b>	February 17, 2015 10:12:35 AM EST
<b>Citable Link</b>	<a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890610">http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890610</a>
<b>Terms of Use</b>	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a>

*(Article begins on next page)*

# BMJ Open Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review

Jessica Mears,<sup>1</sup> Ibrahim Abubakar,<sup>1,2,3</sup> Theodore Cohen,<sup>4</sup> Timothy D McHugh,<sup>5</sup> Pam Sonnenberg<sup>1</sup>

**To cite:** Mears J, Abubakar I, Cohen T, *et al*. Effect of study design and setting on tuberculosis clustering estimates using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR): a systematic review. *BMJ Open* 2015;**5**:e005636. doi:10.1136/bmjopen-2014-005636

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2014-005636>).

Received 12 May 2014

Revised 23 December 2014

Accepted 30 December 2014



CrossMark

For numbered affiliations see end of article.

## Correspondence to

Dr Pam Sonnenberg;  
p.sonnenberg@ucl.ac.uk

## ABSTRACT

**Objectives:** To systematically review the evidence for the impact of study design and setting on the interpretation of tuberculosis (TB) transmission using clustering derived from Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR) strain typing.

**Data sources:** MEDLINE, EMBASE, CINAHL, Web of Science and Scopus were searched for articles published before 21st October 2014.

**Review methods:** Studies in humans that reported the proportion of clustering of TB isolates by MIRU-VNTR were included in the analysis. Univariable meta-regression analyses were conducted to assess the influence of study design and setting on the proportion of clustering.

**Results:** The search identified 27 eligible articles reporting clustering between 0% and 63%. The number of MIRU-VNTR loci typed, requiring consent to type patient isolates (as a proxy for sampling fraction), the TB incidence and the maximum cluster size explained 14%, 14%, 27% and 48% of between-study variation, respectively, and had a significant association with the proportion of clustering.

**Conclusions:** Although MIRU-VNTR typing is being adopted worldwide there is a paucity of data on how study design and setting may influence estimates of clustering. We have highlighted study design variables for consideration in the design and interpretation of future studies.

## INTRODUCTION

The introduction of molecular typing methods has improved our understanding of *Mycobacterium tuberculosis* (TB) transmission and has changed local and national control policies.<sup>1–5</sup> The proportion of cases that are clustered is often used to estimate the amount of ongoing transmission within the population, based on the assumption that

## Strengths and limitations of this study

- This is a timely evaluation of the impact of study design on estimates of tuberculosis clustering using Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats strain typing because it has been incorporated into national typing services globally.
- The strength of this meta-analysis was limited by the lack of detail reported by the included studies, highlighting the need for better quality reporting in primary studies.
- We have shown that the proportion of clustering derived from MIRU-VNTR typing is influenced by the number of loci typed, whether consent is required to type isolates, TB incidence in the study setting, and the maximum cluster size, highlighting these as important considerations in the design and interpretation of future studies.

cases with indistinguishable strain types are part of a chain of transmission. TB molecular typing methodology is changing rapidly and it is important that we better understand how to interpret the outputs and thus act.

TB molecular typing methods include Spoligotyping,<sup>6</sup> insertion sequence 6110 (IS6110) restriction fragment length polymorphism (RFLP) analysis (the recent gold standard),<sup>7</sup> Mycobacterial Interspersed Repetitive Units-Variable Number Tandem Repeats (MIRU-VNTR) typing,<sup>8</sup> and whole genome sequencing.<sup>9–11</sup> Published reviews have identified factors that might influence or bias clustering by IS6110 RFLP.<sup>12 13</sup> No study has repeated this analysis using more up-to-date typing methods, which is important for understanding of the epidemiology of TB and to shape the application of molecular typing to improve TB control.

Published meta-analyses and modelling studies using *IS6110* RFLP data show that the proportion of clustering observed can be affected by (1) study design (affecting the proportion of eligible cases that are included in the study); (2) features of the typing method (such as the ability to type isolates with low copy numbers); and (3) study setting (such as characteristics of the study population). For example, the proportion of clustering increases when the fraction of the total data sampled increases<sup>13–15</sup> and when study duration increases.<sup>16</sup>

MIRU-VNTR is currently the preferred method of molecular typing,<sup>17–21</sup> and can be used together with Spoligotyping.<sup>8</sup> Relative to *IS6110* RFLP, MIRU-VNTR does not have to exclude isolates with a low *IS6110* copy number, has a faster turnaround time, is high throughput and the numeric strain types are more easily compared. MIRU-VNTR strain typing is increasingly being adopted worldwide,<sup>1 22–27</sup> yet unlike *IS6110* RFLP, the evidence for the interpretation of the findings such as the impact of study design and setting on clustering have not been reviewed. Although the two typing methods have been shown to have a similar discriminatory value, the markers evolve independently and at different rates, resulting in a difference in clustering between the two methods.<sup>28</sup> This suggests that there could be differences in the way study design, typing method and setting affects clustering by the two methods. We conducted a systematic review to assess the evidence for the impact of study design and setting on the interpretation of TB transmission using clustering derived from MIRU-VNTR strain typing—as has been shown using *IS6110* RFLP typing.

## METHODS

Five electronic databases were searched (EMBASE, ISI Web of Science, CINHALL, Scopus and Medline (Ovid)) up to 20 October 2014. The search strategy combined the following terms with Boolean operators: Tuberculosis, strain typing, and transmission (see online supplementary appendix 1). The search was limited to studies using the standard MIRU-VNTR method,<sup>8</sup> in humans only, and in English.

All titles and abstracts from each of the searches were examined. The full text of each paper was obtained and reviewed if the study reported MIRU-VNTR strain typing of *M. tuberculosis* complex isolates with at least 15 of the standardised 24 loci (Exact Tandem Repeat A, B, C, D, E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 424, 1955, 2163b, 2347, 2401, 3171, 3690, 4052, 4156).<sup>8 29 30</sup>

Studies using fewer than 15 loci were not included because the level of discrimination is inadequate for epidemiological use (n=121).<sup>8</sup> Studies that used loci different to the standardised 15 and 24 set were not included in the analysis in order to reduce the heterogeneity between studies (n=19). All publication types were included in this first screen to ensure that no relevant data were missed.


Reviews, letters, editorials, outbreaks or case reports (n=103) were excluded in the second screen. Studies that

used incomplete sampling (eg, random samples, studies using subsets of populations such as multidrug-resistant patients; n=47) and studies that had a sample size of less than 50 (n=4) were also excluded.

A reviewer (JM) extracted the following data items from all included studies using a form developed in Excel (Microsoft 2010): publication details (year, authors, study country), study details (study duration, loci typed, secondary typing method, study population, whether participant consent was required (a characteristic of the study design that was used as proxy for sampling fraction, assuming that where consent was required the sampling fraction was low)), the number of clustered and unique isolates and the covariates of interest: the maximum size of clusters; the proportion of clusters containing two cases; the proportion of the population that was culture positive; the proportion of culture positive isolates typed; risk factors for clustering; and the Hunter Gaston Discriminatory Index (HGDI)<sup>31</sup>. IA extracted data from 10% of the papers for external validity, disagreements were discussed and a consensus agreed on.

The main outcome measure—the proportion of TB isolates clustered by MIRU-VNTR strain typing—was calculated as the number of clustered isolates/number of clustered+unique isolates. Where there were uncertainties JM consulted with IA.

Authors were contacted if TB incidence rate was not reported. Where no response was received WHO country estimates of TB incidence for the study year were used.<sup>32</sup> As so few studies reported the proportion coinfected with TB/HIV, these estimates for the study country were taken from an European Union-wide survey and WHO country profiles.<sup>33 34</sup> Owing to poor recording of the sampling fraction (the number of isolates typed/the total number of culture positive TB cases diagnosed during the study period (n=19)), whether the



**Figure 1** Results of systematic search, screening and data extraction.

**Table 1** The study setting and design characteristics of the included articles

Reference	Study setting							Study design								
	Study area and country	TB incidence (per 100 000)	TB/HIV (per 100 000)‡	Previous TB treatment (%)	Pulmonary TB (%)	Maximum cluster size	Clusters of size 2 (%)	Study duration (months)	Study size (clustered +unique isolates)	Culture positive in study population (%)	Culture positive isolates typed (%)	Typing method§	Loci typed¶	Consent required	Risk of bias*	Clustering (%)†
51	New South Wales, Australia	6.7	0.2	0.0	63.7			36	1128			m24	N	no	low	20.1
40	Tabriz and Orumieh, Azarbaijan	26.0		5.2	87.0	5	81.8	12	156		94.5	m15	O	no	low	32.7
52	Brussels-Capital Region, Belgium	35.2	5.1	10.8		23	64.2	24	530	86.1	87.9	m24	N	no	low	29.6
53	Brussels-Capital Region, Belgium	35.2	5.1		100			39	802	81.8	84.7	m24s	N	no	low	28.8
54	Ontario, Canada	4.8	0.4			18	58.8	65	2016			m24s	N	no	low	23.1
37	Changping District, Beijing, China		0.3		100	0		30	318	31.5	94.6	m24	N	no	high	0.0
38	Croatia	19.0	0.1			45	48.3	36	1587			m15	N	no	high	62.8
55	Amhara region, Northwest Ethiopia		24.0	17.6	100	13		5	244			m24	N	yes	low	45.1
56	Finland	5.0	0.0			20		48	1048	75.4	99.4	m15s		no	low	33.9
57	Hamburg, Germany	12.7					45.5	12	154	78.2	91.1	m24s	N	no	low	22.1
45	Schleswig-Holstein, Germany	3.2	0.1			22	44.4	48	277			m24s	N	no	high	27.1
58	South West Ireland	15.3	3.3		82.7	12		36	171	79.5	96.1	m24s	N	no	low	27.5
59	South Tawara, Kiribati	370.0		4.1	100	25	55.6	24	73	45.4	98.6	m24s	N	yes	low	75.3
60	Netherlands	6.5	0.2				57.2	60	3978		100.1	m24	N	no	low	46.7
41	Kharkiv, Russia	94.0	3.8	63.3	100	10	50.0	3	98		100	m15	O	yes	high	31.6
61	Eastern province, Saudi Arabia	4.0			73.1	24	19.0	24	522			m24s	N	no	low	40.2
62	Singapore	40.5	1.2			21	48.0	24	1128	82.0	34.5	m24s	N	no	low	30.8
63	Slovenia	10.6	0.0			6		12	196	94.4	97.5	m24s	N	no	low	36.2
47	Almeria, Spain	26.0	6.0			8		27	281		81.9	m15	N	no	high	43.1
64	Sweden	4.8	0.1			10		36	406			m24s	N	no	low	21.2
65	Mubende, Uganda		86.0	31.1	87.8	11	70.0	6	67	21.5	90.5	m15s	N	yes	low	35.8
42	East Lancashire, UK	18.3	8.2			13	58.3	102	332	48.5	69.9	m15	O	no	low	42.8
39	UK		8.2		42.3	12	50.0	48	102	90.7	87.2	m15	O	no	low	30.4
66	London, UK	44.9	8.2					9	964	36.0	100	m24	N	no		37.0
43	Midlands, UK	15.0	8.2					48	4207	58.3	100	m15	O	no		61.2
44	Odessa and Nikolaev, Ukraine	80.4	3.9	34.2	100			4	225			m15	O	yes**	low	60.4
67	Hanoi, Vietnam	146.0	10.0	0.0	100			20	465	92.7	91.9	m15s	N	yes	low	55.3

\*Risk of bias was assessed using the STROME-ID checklist. Studies scoring <20 were categorised as have a high risk of bias. See online supplementary appendix 2 for STROME-ID scores.

†The proportion of clustering was calculated as the number of clustered isolates/number of clustered+unique isolates.

‡Estimates from of the prevalence of TB/HIV coinfection in the study country.<sup>33 34</sup>

§15=15 MIRU-VNTR loci (made up of the 'old 12' or 'new 12' defined in the footnote below), 24=24 MIRU-VNTR loci (ETR A, B, C, D, E; MIRU 2, 10, 16, 20, 23, 24, 26, 27, 39, 40; VNTR 424, 1955, 2163b, 2347, 2401, 3171, 3690, 4052, 4156), S=with Spoligotyping.

¶O=old 12 MIRU loci (MIRU 2, 4, 10, 16, 20, 23, 24, 26, 27,30, 31, 39, 40), N=new 12 MIRU loci (MIRU 10, 16, 26, 31, 40 +Mtub 04, 21, 39+ETR A C+QUB 11b, 26).

\*\*11.3% did not consent to being part of the study. The other studies that required consent for isolates to be typed did not report the refusal rate.

ETR, Exact Tandem Repeat; TB, tuberculosis.

study required the consent of participants (yes/no) was included as a proxy for (low/high) sampling fraction. The risk of bias within each study was assessed using the STROME-ID checklist.<sup>35</sup>

Data were analysed in Stata V.12. Where studies reported data from more than one set of loci, the method with the highest discriminatory value was included (ie, MIRU-VNTR 24 would be chosen over MIRU-VNTR 15, and MIRU-VNTR 15 plus Spoligotyping would be chosen over MIRU-VNTR 15 alone; n=8). This review was not concerned with summary measures of clustering, but factors that influenced clustering; therefore articles must have included at least one of the covariates. Continuous variables were transformed where the distribution was skewed. The proportion clustered was transformed using the Freeman Tukey transformation.<sup>36</sup> Study heterogeneity was assessed using a forest plot and the  $\chi^2$  test of heterogeneity. Univariable meta-regression analyses were carried out to determine the effect of the study design covariates on the proportion of clustered isolates. All covariates in the analysis were hypothesised to influence the proportion clustered a priori.

Sensitivity analyses were conducted to see the effect of removing studies reporting 0% clustering, with only extrapulmonary TB cases, only *Mycobacterium bovis* cases, studies using the 'old 12' MIRU loci as part of their 15 loci, and studies assessed as having a high likelihood of bias (STROME-ID score less than 20).

## RESULTS

The search identified 7274 references resulting in 27 studies (25 journal articles and 2 conference abstracts) included after deduplication and title/abstract/full text screening (figure 1). The main characteristics of the

included studies are shown in table 1. Studies were published between 2007 and 2014 and the clustering reported varied from 0%<sup>37</sup> to 62.8%.<sup>38</sup> In all studies, clustered isolates were defined as having identical strain types based on the MIRU-VNTR loci typed, with or without Spoligotyping. Seventeen studies included isolates from newly diagnosed TB cases, three studies reported including isolates from new and chronic cases of TB, and seven did not report this information. In addition, 10 studies did not include repeat isolates from the same patient, one study included a repeat isolate from one patient and the remaining 17 did not report whether repeat isolates were included or not. Furthermore, four studies included isolates with missing loci in the cluster analysis, whereas four excluded isolates with missing loci and the remaining 20 did not report how they dealt with missing loci. The number of studies reporting each variable of interest is shown in table 2. STROME-ID scores can be found in online supplementary appendix 2.

A forest plot shows the spread of clustering reported by number of loci and additional typing method (figure 2). Significant heterogeneity was identified between the studies ( $p<0.001$ ), suggesting that a meta-regression would be an appropriate analysis.


The univariable meta-regression shows evidence for the proportion of clustering to decrease as the number of MIRU-VNTR loci typed increased from 15 to 24 ( $p=0.04$ ; table 3), accounting for 14% of the between study variation, and to increase when the study participants consented to being included in the study ( $p=0.03$ ), accounting for 14% of the between study variation. The proportion of clustering increased as the TB incidence in the population increased ( $p=0.007$ , adjusted  $R^2=26.7$ ). There was also evidence for the proportion of clustering

**Table 2** The number of studies that reported the variables of interest

	Reported	Missing
Study setting		
TB incidence	8	15
TB/HIV coinfection	5	22
Previous TB treatment	9	18
Proportion pulmonary TB	14	13
Maximum cluster size	19	8
Percentage of clusters with 2 cases	14	13
Study design		
Study duration	27	0
Study size	27	0
Percentage of population that is culture positive	15	12
Percentage of culture positive typed	19	8
24 loci (compared to 15)	27	0
Repeat isolates	12	15
Missing loci	8	19
Double alleles	1	26
Consent required	6*	21
Epidemiological information	6	21

\*Only one study reported the consent rate. TB, tuberculosis.





**Figure 2** Forest plot showing the proportion of clustering reported in each study by the number of MIRU-VNTR loci typed. The number of loci typed is categorised into 15 loci (m15), 15 loci with Spoligotyping (m15 s), 24 loci (m24) and 24 loci with Spoligotyping (m24 s). The study reference is shown in the right hand column.

to increase as the maximum cluster size increased ( $p=0.001$ ), accounting for 48% of between study variation. There was no evidence of the other study design or study setting variables significantly influencing the proportion clustered. Though non-significant ( $p>0.05$ ), the TB/HIV coinfection rate in the population explained 2% of the between study variation. Too few studies included information on the proportion of clusters containing two cases, proportion of the study sample with previous TB or with pulmonary TB, so these could not be included in the analysis (table 2).

Sensitivity analyses to examine the effect of excluding studies reporting 0% clustering,<sup>37</sup> only *M. bovis* cases,<sup>39</sup> studies using the 'old 12' MIRU loci,<sup>39-44</sup> and studies assessed as having a high risk of bias,<sup>37 38 45-47</sup> did not generally change the results. The proportion of culture-positive TB in the population remained insignificant but

explained 2.6% of the between study variation when excluding 0% clustering ( $p=0.278$  and adjusted  $R^2=2.62$ ). Similarly, the proportion of culture-positive TB in the population remained insignificant but explained 2.6% of the between study variation when excluding studies with the highest risk of bias ( $p=0.278$  and adjusted  $R^2=2.62$ ). The number of loci typed became non-significant, but explained 9.6% and 10.5% of the between study variation when excluding studies using the 'old 12' loci and the highest risk of bias, respectively ( $p=0.106$ , adjusted  $R^2=9.63$ ;  $p=0.111$ , adjusted  $R^2=10.51$ , respectively).

## DISCUSSION

This review identified 27 studies that met the inclusion criteria. We illustrate that the interpretation of studies

**Table 3** Univariable metaregression showing the coefficients for change in the proportion of clustering and the percentage of between-study variation explained by variables describing the study design and setting

	n	Coefficient*	CI	p Value	Adjusted R <sup>2</sup> †
<b>Study setting</b>					
TB incidence	23	0.14	0.04 to 0.24	0.007	26.74
TB/HIV coinfection	23	0.04	−0.03 to 0.11	0.246	2.00
Maximum cluster size	19	0.20	0.09 to 0.30	0.001	48.20
<b>Study design</b>					
Study duration	27	−0.02	−0.09 to 0.06	0.677	−3.37
Percentage of population that is culture positive	15	0.34	−1.23 to 1.96	0.661	−5.92
Percentage of culture positive typed	19	0.22	−1.08 to 1.52	0.725	−5.41
Study size	27	0.03	−0.11 to 0.16	0.702	−3.31
24 loci (compared to 15)	27	−0.30	−0.59 to −0.01	0.04	13.58
Consent required	27	0.38	0.04 to 0.72	0.029	14.41

\*Coefficients for the change in the proportion of clustering for each covariate. For example, for a one unit increase in maximum cluster size, the proportion of clustering increases by 0.2.

†The proportion of between-study variation explained by the univariate metaregression.  
TB, tuberculosis.

using MIRU-VNTR to estimate clustering is subject to bias relating to study design and setting; however, there were insufficient data available to fully explore this impact.

As expected, we found that the proportion of clustering decreased with a greater number of MIRU-VNTR loci typed, with increasing TB incidence and with increasing maximum cluster size. We found that requiring consent to type patient isolates increased the proportion of clustering, which is not expected, given that the sampling fraction would be lower in these studies.

The other study design variables included in this analysis, such as study duration, did not significantly influence the proportion of isolates that were clustered, contrary to previous findings.<sup>12</sup> This is likely to be because of a lack of good quality evidence: of the 27 studies that met the inclusion criteria for the review, none reported all the variables of interest, reducing the power of the analysis and precluding multivariable metaregression (table 2). Importantly, key details of cluster analyses were not reported consistently across the studies, such as whether repeat isolates from the same patients were included, or typing profiles with missing loci were included, introducing new, unmeasured biases. In addition, the range of the variables may have been too limited to show any impact on clustering estimates. For example, the proportion of culture-positive isolates typed ranged from 34.5% to 100%, with 17 of the 19 studies reporting this variable from 81.9% to 100%. Furthermore, most of the studies (17/27=63%) were from low TB burden settings and therefore may be reflecting the rate at which imported cases have matching strain types by chance, rather than rates of recent transmission.

The sensitivity analysis suggested that, when excluding the studies with the greatest risk of bias, the culture-positivity in the population might explain a small amount of the between-study variation. This is consistent with estimates of the influence of sampling on the

proportion of clustering using IS6110 RFLP typing.<sup>48</sup> In the sensitivity analysis excluding studies that used the ‘old 12’ loci, the effect of the number of loci typed becomes non-significant. This is likely because studies using the ‘old 12’ accounted for six out of 10 studies reporting 15 loci, reducing the number of studies and the power of the model.

This study is a timely evaluation of the impact of study design on estimates of TB clustering using MIRU-VNTR strain typing because it has been incorporated into national typing services globally.<sup>23 49</sup> The findings are relevant where strain typing is used to evaluate TB control systems across different settings because the proportion of clustering is influenced by the number of loci typed, the TB incidence and the maximum cluster size. Given that strain typing methods are advancing beyond MIRU-VNTR typing and that the application of whole genome sequencing to TB control and public health strategies has been demonstrated,<sup>9–11 50</sup> it is important that the biases in the analysis of such methods are explored and compared. Understanding how to design and compare research studies for public health will greatly improve the benefit gained from newer technologies.

The strength of this meta-analysis was limited by the (lack of) detail reported by the included studies. This review has highlighted the need for better quality reporting in primary studies to enable future reviews to be more robust. Recently published standards for reporting of molecular epidemiology for infectious diseases should improve the quality of reporting.<sup>35</sup> This review is further limited by our inability to access 58 of the title/abstract screened articles for full text screening.

The use of TB strain typing as a public health tool in TB control programmes is increasing globally. We have identified a lack of good quality studies that can contribute to our understanding in interpreting the molecular typing of TB. We have also shown that the proportion of clustering derived from MIRU-VNTR typing is influenced by the number of loci typed, whether consent is

required to type isolates, TB incidence in the study setting and the maximum cluster size, highlighting these as important considerations in the design and interpretation of future studies.

#### Author affiliations

<sup>1</sup>Department of Infection and Population Health, University College London, London, UK

<sup>2</sup>Centre for Infectious Disease Surveillance and Control, Public Health England, London, UK

<sup>3</sup>Clinical Trials Unit, Medical Research Council, London, UK

<sup>4</sup>Division of Global Health Equity, Brigham and Women's Hospital and Department of Epidemiology, Harvard School of Public Health, Harvard University, Boston, USA

<sup>5</sup>Department of Infection, Centre for Clinical Microbiology, University College London, London, UK

**Acknowledgements** The authors would like to acknowledge Ross Harris from the Statistics Unit at Public Health England for his advice on metaregression.

**Contributors** JM drafted the article and PS, IA, TDM and TC revised it critically for important intellectual content. All authors made substantial contributions to the conception and design of the review, and the analysis and interpretation of data. All authors approved the final version for publication.

**Funding** Public Health England and University College London Impact Studentship. JM is funded through a Public Health England and University College London Impact Studentship. IA is funded through a NIHR Senior Research Fellowship

**Competing interests** None.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** No additional data are available.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

- Lambregts-van Weezenbeek CSB, Sebek MMGG, van Gerven PJHJ, *et al.* Tuberculosis contact investigation and DNA fingerprint surveillance in The Netherlands: 6 years' experience with nationwide cluster feedback and cluster monitoring. *Int J Tuberc Lung Dis* 2003;7:S463–470.
- Borgdorff MW, van den Hof S, Kremer K, *et al.* Progress towards tuberculosis elimination: secular trend, immigration and transmission. *Eur Respir J* 2010;36:339–47.
- Kik SV, Verver S, Van Soolingen D, *et al.* Tuberculosis outbreaks predicted by characteristics of first patients in a DNA fingerprint cluster. *Am J Respir Crit Care Med* 2008;178:96–104.
- Small PM, McClenny NB, Singh SP, *et al.* Molecular strain typing of Mycobacterium tuberculosis to confirm cross-contamination in the mycobacteriology laboratory and modification of procedures to minimize occurrence of false-positive cultures. *J Clin Microbiol* 1993;31:1677–82.
- De Vries G, van Hest RAH, Richardus JH. Impact of mobile radiographic screening on tuberculosis among drug users and homeless persons. *Am J Respir Crit Care Med* 2007;176:201–7.
- Kamerbeek J, Schouls L, Kolk A, *et al.* Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. *J Clin Microbiol* 1997;35:907–14.
- Van Embden JD, Cave MD, Crawford JT, *et al.* Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. *J Clin Microbiol* 1993;31:406–9.
- Supply P, Allix C, Lesjean S, *et al.* Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. *J Clin Microbiol* 2006;44:4498–510.
- Schürch AC, van Soolingen D. DNA fingerprinting of Mycobacterium tuberculosis: from phage typing to whole-genome sequencing. *Infect Genet Evol* 2012;12:602–9. <http://www.ncbi.nlm.nih.gov/pubmed/22067515> (accessed 13 Mar 2012).
- Gardy JL, Johnston JC, Ho Sui SJ, *et al.* Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. *N Engl J Med* 2011;364:730–9.
- Walker TM, Ip CL, Harrell RH, *et al.* Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. *Lancet Infect Dis* 2013;13:137–46.
- Houben RMGJ, Glynn JR. A systematic review and meta-analysis of molecular epidemiological studies of tuberculosis: development of a new tool to aid interpretation. *Trop Med Int Health* 2009;14:892–909.
- Fok A, Numata Y, Schulzer M, *et al.* Risk factors for clustering of tuberculosis cases: a systematic review of population-based molecular epidemiology studies. *Int J Tuberc Lung Dis* 2008;12:480–92.
- Borgdorff MW, Van Den Hof S, Kalisvaart N, *et al.* Influence of sampling on clustering and associations with risk factors in the molecular epidemiology of tuberculosis. *Am J Epidemiol* 2011;174:243–51. <http://aje.oxfordjournals.org/content/early/2011/05/23/aje.kwr061> (accessed 29 Mar 2012).
- Glynn JR, Bauer J, de Boer AS, *et al.* Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. European concerted action on molecular epidemiology and control of tuberculosis. *Int J Tuberc Lung Dis* 1999;3:1055–60.
- Glynn JR, Crampin AC, Yates MD, *et al.* The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi. *J Infect Dis* 2005;192:480–7.
- De Beer JL, Kremer K, Ködmön C, *et al.* First worldwide proficiency study on variable-number tandem-repeat typing of Mycobacterium tuberculosis complex strains. *J Clin Microbiol* 2012;50:662–9.
- Maes M, Kremer K, van Soolingen D, *et al.* 24-locus MIRU-VNTR genotyping is a useful tool to study the molecular epidemiology of tuberculosis among Warao Amerindians in Venezuela. *Tuberculosis (Edinb)* 2008;88:490–4.
- Sougakoff W. Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis. *Clin Microbiol Infect* 2011;17:800–5.
- Weniger T, Krawczyk J, Supply P, *et al.* MIRU-VNTRplus: a web tool for polyphasic genotyping of Mycobacterium tuberculosis complex bacteria. *Nucleic Acids Res* 2010;38:W326–31.
- Supply P. MIRU-VNTR typing: the new international standard for TB molecular epidemiology Symposium of the Institut Pasteur de Tunisia, 2010.
- Van Soolingen D, Borgdorff MW, de Haas PE, *et al.* Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. *J Infect Dis* 1999;180:726–36.
- Cowan LS, Diem L, Monson T, *et al.* Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. *J Clin Microbiol* 2005;43:688–95.
- Centers for Disease Control and Prevention. New CDC program for rapid genotyping of Mycobacterium tuberculosis isolates. *JAMA* 2005;293:2086–2086.
- Bauer J, Kok-Jensen A, Faurschou P, *et al.* A prospective evaluation of the clinical value of nation-wide DNA fingerprinting of tuberculosis isolates in Denmark. *Int J Tuberc Lung Dis* 2000;4:295–9.
- Bauer J, Yang Z, Poulsen S, *et al.* Results from 5 years of nationwide DNA fingerprinting of Mycobacterium tuberculosis complex isolates in a country with a low incidence of M. tuberculosis infection. *J Clin Microbiol* 1998;36:305–8.
- Zolnir-Dovc M, Poljak M, Erzen D, *et al.* Molecular epidemiology of tuberculosis in Slovenia: results of a one-year (2001) nation-wide study. *Scand J Infect Dis* 2003;35:863–8.
- Hanekom M, van der Spuy GD, Gey van Pittius NC, *et al.* Discordance between mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing and IS6110 restriction fragment length polymorphism genotyping for analysis of Mycobacterium tuberculosis Beijing strains in a setting of high incidence of tuberculosis. *J Clin Microbiol* 2008;46:3338–45.
- Supply P, Lesjean S, Savine E, *et al.* Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. *J Clin Microbiol* 2001;39:3563–71.
- Gopaul KK, Brown TJ, Gibson AL, *et al.* Progression toward an improved DNA amplification-based typing technique in the study of Mycobacterium tuberculosis epidemiology. *J Clin Microbiol* 2006;44:2492–8.



31. Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity. *J Clin Microbiol* 1988;26:2465–6.
32. WHO/ITB data (n.d.). WHO. <http://www.who.int/tb/country/en/index.html> (accessed 12 Dec 2012).
33. Kruijshaar ME, Pimpin L, Abubakar I, *et al*. The burden of TB-HIV in the EU: how much do we know? A survey of surveillance practices and results. *Eur Respir J* 2011;38:1374–81.
34. World Health Organization (n.d.). WHO Tuberculosis Country Profiles. <http://www.who.int/tb/country/data/profiles/en/>
35. Field N, Cohen T, Struelens MJ, *et al*. Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. *Lancet Infect Dis* 2014;14:341–52.
36. Freeman MF, Tukey JW. Transformations related to the angular and the square root. *Ann Math Statist* 1950;21:607–11.
37. Guang-ming D, Zhi-guo Z, Peng-ju D, *et al*. Differences in the population of genetics of Mycobacterium tuberculosis between urban migrants and local residents in Beijing, China. *Chin Med J* 2013;126:4066–71.
38. Zmak L, Obrovac M, Katalinic Jankovic V. First insights into the molecular epidemiology of tuberculosis in Croatia during a three-year period, 2009 to 2011. *Scand J Infect Dis* 2014;46:123–9.
39. Mandal S, Bradshaw L, Anderson LF, *et al*. Investigating transmission of Mycobacterium bovis in the United Kingdom in 2005 to 2008. *J Clin Microbiol* 2011;49:1943–50.
40. Asgharzadeh M, Kafil HS, Roudsary AA, *et al*. Tuberculosis transmission in Northwest of Iran: using MIRU-VNTR, ETR-VNTR and IS6110-RFLP methods. *Infect Genet Evol* 2011;11:124–31.
41. Dymova MA, Liaschenko OO, Poteiko PI, *et al*. Genetic variation of Mycobacterium tuberculosis circulating in Kharkiv Oblast, Ukraine. *BMC Infect Dis* 2011;11:77.
42. Sails AD, Barrett A, Sarginson S, *et al*. Molecular epidemiology of Mycobacterium tuberculosis in East Lancashire 2001–2009. *Thorax* 2011;66:709–13.
43. Evans J. *Analysis of prevalent Mycobacterium tuberculosis strains in the United Kingdom: detection, distribution and expansion of MIRU-VNTR profiles containing high numbers of isolates*. Vienna, Austria: European Society of Clinical Microbiology and Infectious Diseases, 2010.
44. Nikolayevskyy VV, Brown TJ, Bazhora YI, *et al*. Molecular epidemiology and prevalence of mutations conferring rifampicin and isoniazid resistance in Mycobacterium tuberculosis strains from the southern Ukraine. *Clin Microbiol Infect* 2007;13:129–38.
45. Roetzer A, Schuback S, Diel R, *et al*. Evaluation of Mycobacterium tuberculosis typing methods in a 4-year study in Schleswig-Holstein, Northern Germany. *J Clin Microbiol* 2011;49:4173–8.
46. Dymova MA, Kinsht VN, Cherednichenko AG, *et al*. Highest prevalence of the Mycobacterium tuberculosis Beijing genotype isolates in patients newly diagnosed with tuberculosis in the Novosibirsk oblast, Russian Federation. *J Med Microbiol* 2011;60:1003–9.
47. Alonso-Rodriguez N, Martínez-Lirola M, Sánchez ML, *et al*. Prospective universal application of mycobacterial interspersed repetitive-unit-variable-number tandem-repeat genotyping to characterize Mycobacterium tuberculosis isolates for fast identification of clustered and orphan cases. *J Clin Microbiol* 2009;47:2026–32.
48. Glynn JR, Vyonycky E, Fine PEM. Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. *Am J Epidemiol* 1999;149:366–71.
49. TB Strain Typing Project Board HPA. TB Strain Typing Cluster Investigation Handbook for Health Protection Units 1st Edition. 2011. <https://hpaintranet.hpa.org.uk/Content/ProgrammesProjects/HPAProgrammes/HPAKeyHealthProtectionProgrammes/Respiratory/TB/StrainTyping/> (accessed 30 Nov 2011).
50. Walker TM, Monk P, Grace Smith E, *et al*. Contact investigations for outbreaks of Mycobacterium tuberculosis: advances through whole genome sequencing. *Clin Microbiol Infect* 2013;19:796–802.
51. Gurjav U, Jeffs P, McCallum N, *et al*. Temporal dynamics of Mycobacterium tuberculosis genotypes in New South Wales, Australia. *BMC Infect Dis* 2014;14:455–5.
52. Allix-Béguec C, Fauville-Dufaux M, Supply P. Three-year population-based evaluation of standardized mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing of Mycobacterium tuberculosis. *J Clin Microbiol* 2008;46:1398–406.
53. Allix-Béguec C, Supply P, Wanlin M, *et al*. Standardised PCR-based molecular epidemiology of tuberculosis. *Eur Respir J* 2008;31:1077–84.
54. Tuite AR, Guthrie JL, Alexander DC, *et al*. Epidemiological evaluation of spatiotemporal and genotypic clustering of mycobacterium tuberculosis in Ontario, Canada. *Int J Tuberc Lung Dis* 2013;17:1322–7.
55. Tessema B, Beer J, Merker M, *et al*. Molecular epidemiology and transmission dynamics of Mycobacterium tuberculosis in Northwest Ethiopia: new phylogenetic lineages found in Northwest Ethiopia. *BMC Infect Dis* 2013;13:131.
56. Smit PW, Haanpera M, Rantala P, *et al*. Molecular Epidemiology of Tuberculosis in Finland, 2008–2011. *PLoS ONE* 2013; 8:e85027.
57. Oelemann MC, Diel R, Vatin V, *et al*. Assessment of an optimized mycobacterial interspersed repetitive-unit-variable-number tandem-repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. *J Clin Microbiol* 2007;45:691–7.
58. Ojo OO, Sheehan S, Corcoran DG, *et al*. Molecular epidemiology of Mycobacterium tuberculosis clinical isolates in Southwest Ireland. *Infect Genet Evol* 2010;10:1110–16.
59. Aleksic E, Merker M, Cox H, *et al*. First Molecular Epidemiology Study of Mycobacterium tuberculosis in Kiribati. *PLoS ONE* 2013;8:e55423. <http://www.scopus.com/inward/record.url?eid=2-s2.0-84873163328&partnerID=40&md5=3994b8e5638129b621abc4d7d6d5e3b8> <http://dx.doi.org/10.1371/journal.pone.0055423>
60. De Beer JL, van Ingen J, de Vries G, *et al*. Comparative study of IS6110 restriction fragment length polymorphism and variable-number tandem-repeat typing of Mycobacterium tuberculosis isolates in the Netherlands, based on a 5-year nationwide survey. *J Clin Microbiol* 2013;51:1193–8.
61. Varghese B, Supply P, Shoukri M, *et al*. Tuberculosis transmission among immigrants and autochthonous populations of the Eastern Province of Saudi Arabia. *PLoS ONE* 2013;8:e77635. <http://www.scopus.com/inward/record.url?eid=2-s2.0-84885784886&partnerID=40&md5=4fdbf4015a999a9fcd1a1c31207a75a2>
62. Lim LK-Y, Sng LH, Win W, *et al*. Molecular epidemiology of Mycobacterium tuberculosis complex in Singapore, 2006–2012. *PLoS ONE* 2013;8:e84487.
63. Bidovec-Stojkovic U, Zolnir-Dovc M, Supply P. One year nationwide evaluation of 24-locus MIRU-VNTR genotyping on Slovenian Mycobacterium tuberculosis isolates. *Respir Med* 2011;105(Suppl 1):S67–73.
64. Jonsson J, Hoffner S, Berggren I, *et al*. Comparison between RFLP and MIRU-VNTR genotyping of mycobacterium tuberculosis strains isolated in stockholm 2009 to 2011. *PLoS ONE* 2014;9:e95159. <http://www.plosone.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0095159&representation=PDF>
65. Muwonge A, Malama S, Johansen TB, *et al*. Molecular epidemiology, drug susceptibility and economic aspects of tuberculosis in Mubende District, Uganda. *PLoS ONE* 2013;8:e64745. <http://www.scopus.com/inward/record.url?eid=2-s2.0-84878608813&partnerID=40&md5=babbd6d006ca64e327fb19e01b6bc697>
66. Hamblin EL, Wynne-Edwards E, Anderson C, *et al*. A summary of strain typing and clustering of TB in London in 2010 and an analysis of the associated risk factors. *Thorax* 2011;66:A88–9.
67. Hang NTL, Maeda S, Lien LT, *et al*. Primary drug-resistant tuberculosis in Hanoi, Vietnam: present status and risk factors. *PLoS ONE* 2013;8:e71867. UNSP.